Bayer U.S. LLC
Bayer was the first pharmaceutical company to successfully operationalize Kits4Life, a first-of-its kind program to enable donations of unused clinical trial supplies for humanitarian aid. This was realized due to the system-changing collaboration between Bayer and Kits4Life partners of MedSurplus Alliance and Hospital Sisters Mission Outreach. By allowing direct excess to product from all of Bayer US sites, healthcare delivery efforts are strengthened, while positively impacting thousands of lives.
Bayer is working with Kits4Life to expand the model globally. Bayer’s goal is to make this standard in all of its clinical trials and ultimately a Pharma industry standard. This ground-breaking program can greatly expand the distribution of currently unused clinical trial supplies to under-resourced settings, closing the healthcare gap worldwide and achieving Health for All.
Eli Lilly and Company
2021 marks 100 years since the discovery of insulin, and global estimates indicate that 300,000 children – almost all in low- and middle-income countries (LMICs) – still lack adequate insulin access. For children and young people with type 1 diabetes, lack of insulin access remains the main cause of death.
In response, Eli Lilly and Company has partnered with Life for a Child and Direct Relief to deliver diabetes support, including insulins, to vulnerable children and young people in LMICs. Since 2009, Lilly has donated more than 28 million mL of insulin to this effort, in addition to covering the costs of arranging, packing, and shipping the insulin to beneficiaries. Starting in 2021, the partnership will expand access to care for youth with diabetes from about 23,000 in 2020 to approximately 150,000 over the next 10 years.
Since 2017, Pfizer has partnered with Direct Relief to make 1 million doses of overdose-reversing naloxone available at no cost to qualified U.S. nonprofit health care providers and local public health departments on the front lines of the rising opioid epidemic. At the height of the COVID-19 pandemic, Direct Relief saw an increase in requests from its network and Pfizer provided an additional 500,000 doses to meet the growing need. In late 2020, Pfizer made a second commitment of 1 million doses to continue reliable access.
Direct Relief has distributed nearly 2 million doses of Pfizer donated naloxone, at no cost, to 834 nonprofit health centers, free clinics, public health departments, harm reduction organizations, and other opioid overdose prevention and treatment organizations throughout the U.S., D.C., and Puerto Rico to help prevent overdose deaths.